We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Aggressive New HIV Strain Leads to AIDS Faster

By HospiMedica International staff writers
Posted on 11 Dec 2013
A new aggressive strain of human immunodeficiency virus (HIV) develops more rapidly into acquired immunodeficiency syndrome (AIDS) than other current strains.

Human immunodeficiency virus type 1 (HIV-1) is characterized by a high genetic diversity, a consequence of an extremely high replication rate, an error-prone reverse transcriptase, recombination events during replication, and host selective immune pressure. More...
HIV-1 is divided into subtypes and the impact circulating recombinant forms (CRFs) need to be investigated.

Scientists at the Lund University (Sweden) analyzed blood samples obtained from individuals enrolled in a cohort comprising police officers in Guinea-Bissau. The cohort includes 225 HIV-1 seroincident individuals with estimated dates of seroconversion, defined as the midpoint between the last seronegative and the first seropositive sample. In total, samples were available for 191 individuals.

Viral ribonucleic acid (RNA) was extracted from blood plasma samples amplified by reverse-transcription polymerase chain reaction, and the C2–V3 region (460 bp) sequenced. Clones were amplified using Platinum Taq DNA Polymerase High Fidelity (Invitrogen, Carlsbad, CA, USA) and conventional M13 primers (−20 and −24) and sequenced using primers JA170, JA169 or M13 reverse primer.

The major subtypes/CRFs identified were CRF02_AG (53%), A3 (29%), and A3/02 (a recombinant of A3 and CRF02_AG) (13%). Infection with A3/02 was associated with a close to three-fold increased risk of AIDS and AIDS-related death compared to A3, respectively. The estimated time from seroconversion to AIDS and AIDS-related death was 5 and 8 years for A3/02, 6 and 9 years for CRF02_AG, and 7 and 11 years for A3.

Patrik Medstrand, PhD, professor of Clinical Virology at Lund University, said, “HIV is an extremely dynamic and variable virus. New subtypes and recombinant forms of HIV-1 have been introduced to our part of the world, and it is highly likely that there are a large number of circulating recombinants of which we know little or nothing. We therefore need to be aware of how the HIV-1 epidemic changes over time.” The study was published in the November 2103 issue of the Journal of Infectious Diseases.

Related Links:

Lund University
Invitrogen 



Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Half Apron
Demi
Hemostatic Agent
HEMOBLAST Bellows
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.